National Comprehensive Cancer Network

NCCN Research & Business Resources

Octreotide therapy for asymptomatic patients with recurrent, unresectable carcinoid tumors added to Neuroendocrine Tumors Guidelines

The NCCN Clinical Practice Guidelines in Oncology™ for Neuroendocrine Tumors have been updated to include octreotide therapy as a new management option for asymptomatic patients with recurrent, unresectable carcinoid tumors as a category 2A recommendation. This addition is based on recently published interim results of a placebo controlled phase III trial (PROMID).

Other updates include the expansion of the Neuroendocrine Tumor Guidelines to include the management of adrenal gland tumors (including adrenocortical tumors, incidentaloma and adrenal carcinoma). The management of adrenal tumors was previously addressed in the context of MEN-1 syndromes. The updated Neuroendocrine Tumor Guidelines also include recommendations for management of neuroendocrine tumors of unknown primary cancers and surgical principles for management of neuroendocrine tumors.

View the complete updated version of the NCCN Neuroendocrine Tumors Guideline.